Pancreatic Cancer Research

Clinical trialPhase 2Active not recruiting

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

Outcome
Ongoing
Phase
Phase 2
Status
Active not recruiting
Study type
Interventional
Start
30 November 2016
Expected end
30 September 2027
Enrollment
10 participants
Sites
9
Primary outcomes
Frequency and types of adverse events and serious adverse events
Sponsor type
Industry
Results posted
No
Last update
17 August 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.